British Journal of Hospital Medicine,
Journal Year:
2024,
Volume and Issue:
85(11), P. 1 - 13
Published: Nov. 30, 2024
Aims/Background
Primary
hypercholesterolemia
(PHC)
is
a
major
risk
factor
for
atherosclerotic
cardiovascular
disease
(ASCVD).
Although
the
fact
that
statins
effectively
lower
low-density
lipoprotein
cholesterol
(LDL-C)
levels,
some
patients
fail
to
achieve
target
LDL-C
levels
and
continue
have
high
of
disease.
This
study
aims
evaluate
clinical
efficacy
safety
ezetimibe
combined
with
rosuvastatin
in
PHC.
Methods
retrospectively
examined
101
PHC
who
received
at
cardiology
department
Jilin
Province
FAW
General
Hospital,
between
2021
2024.
Patients
were
divided
into
observation
(ezetimibe
rosuvastatin,
n
=
45)
control
(rosuvastatin,
66)
groups
accordance
their
treatment
regimens.
Data
sourced
from
hospital's
electronic
health
records
system,
statistical
analysis
was
performed
by
using
SPSS
25.0
software
(IBM
Corporation,
Armonk,
NY,
USA).
Results
Baseline
characteristics
similar
two
groups.
After
12
weeks
treatment,
reduction
group
(–0.373
[–0.427,
–0.348])
greater
than
(–0.240
[–0.318,
–0.222],
p
<
0.001).
The
percentage
changes
total
(TC),
triglyceride
(TG),
high-density
(HDL-C)
significantly
better
(TC:
–0.230
[–0.302,
–0.144],
TG:
–0.292
[–0.333,
–0.237],
HDL-C:
0.081
[0.067,
0.111])
–0.127
[–0.158,
–0.119],
–0.082
[–0.101,
–0.067],
0.000
[–0.163,
0.133]
0.001,
0.011,
respectively).
Regarding
drug
safety,
incidence
adverse
events
comparable
(11.10%
vs.
12.10%,
0.871).
Conclusion
combination
demonstrates
superior
lipid-lowering
good
inadequately
controlled
statin
therapy,
providing
an
effective
alternative
option.
Further
large-scale,
multicenter
randomized
trials
are
warranted
confirm
its
long-term
safety.
Natural Resources for Human Health,
Journal Year:
2024,
Volume and Issue:
4(3), P. 208 - 229
Published: June 5, 2024
ATP
Citrate
Lyase
(ACLY)
is
a
central
enzyme
bridging
carbohydrate
metabolism
and
lipid
biosynthesis,
crucial
for
various
physiological
processes
implicated
in
numerous
pathologies.
This
review
comprehensively
describes
ACLY,
pivotal
at
biosynthesis
cellular
interface.
It
serves
as
role
several
functions,
making
it
highly
valued
topic
research.
Starting
with
description
of
the
biochemistry
molecular
biology
elucidating
its
structural
features,
regulatory
mechanisms,
particularly
synthesis
histone
acetylation.
Considering
pathophysiological
aspect,
also
examines
relationship
between
ACLY
dysregulation
associated
diseases,
explaining
contribution
to
pathological
conditions
mechanistically.
An
explanation
inhibitors
follows:
an
overview
these
inhibitors,
understanding
their
mechanisms
action,
analysis
effectiveness
specificity.
The
following
sections
transition
from
preclinical
studies,
summarising
key
findings
knowledge
into
therapeutic
potential,
clinical
trials.
offers
updated
information
about
research,
integrating
data
multiple
sources
give
in-depth
understanding.
concludes
challenges
outlook
facing
developing
considering
strategies
overcome
upcoming
path
research
development
this
promising
field.
comprehensive
examination
not
only
encapsulates
present
but
aims
inspire
guide
future
inquiries
complex
realm
potential
target,
ultimately
improving
patient
outcomes
quality
life.
AIDS,
Journal Year:
2024,
Volume and Issue:
38(11), P. 1720 - 1721
Published: Aug. 1, 2024
HAND
Research
Group,
School
of
Medicine
and
Health
Sciences,
Mulungushi
University,
Livingstone,
Zambia.
Correspondence
to
Sepiso
K.
Masenga,
Akapelwa
street,
E-mail:
[email
protected]
Received
7
June,
2024
Accepted
9
British Journal of Hospital Medicine,
Journal Year:
2024,
Volume and Issue:
85(11), P. 1 - 13
Published: Nov. 30, 2024
Aims/Background
Primary
hypercholesterolemia
(PHC)
is
a
major
risk
factor
for
atherosclerotic
cardiovascular
disease
(ASCVD).
Although
the
fact
that
statins
effectively
lower
low-density
lipoprotein
cholesterol
(LDL-C)
levels,
some
patients
fail
to
achieve
target
LDL-C
levels
and
continue
have
high
of
disease.
This
study
aims
evaluate
clinical
efficacy
safety
ezetimibe
combined
with
rosuvastatin
in
PHC.
Methods
retrospectively
examined
101
PHC
who
received
at
cardiology
department
Jilin
Province
FAW
General
Hospital,
between
2021
2024.
Patients
were
divided
into
observation
(ezetimibe
rosuvastatin,
n
=
45)
control
(rosuvastatin,
66)
groups
accordance
their
treatment
regimens.
Data
sourced
from
hospital's
electronic
health
records
system,
statistical
analysis
was
performed
by
using
SPSS
25.0
software
(IBM
Corporation,
Armonk,
NY,
USA).
Results
Baseline
characteristics
similar
two
groups.
After
12
weeks
treatment,
reduction
group
(–0.373
[–0.427,
–0.348])
greater
than
(–0.240
[–0.318,
–0.222],
p
<
0.001).
The
percentage
changes
total
(TC),
triglyceride
(TG),
high-density
(HDL-C)
significantly
better
(TC:
–0.230
[–0.302,
–0.144],
TG:
–0.292
[–0.333,
–0.237],
HDL-C:
0.081
[0.067,
0.111])
–0.127
[–0.158,
–0.119],
–0.082
[–0.101,
–0.067],
0.000
[–0.163,
0.133]
0.001,
0.011,
respectively).
Regarding
drug
safety,
incidence
adverse
events
comparable
(11.10%
vs.
12.10%,
0.871).
Conclusion
combination
demonstrates
superior
lipid-lowering
good
inadequately
controlled
statin
therapy,
providing
an
effective
alternative
option.
Further
large-scale,
multicenter
randomized
trials
are
warranted
confirm
its
long-term
safety.
